Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 382

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 382
---
 Six MonthsEnded June 30, |   |           |   |   |   |      |   |           |   | ​ |
| ​                                             | ​ | ​ |                               2025 |   |           |   | ​ | ​ | 2024 |   |           |   | ​ | ​ |                             2025 |   |           |   | ​ | ​ | 2024 |   |           |   | ​ |
| Preferred Stock (as converted to commonstock) | ​ | ​ |                                  ​ | ​ |         — | ​ | ​ | ​ |    ​ | ​ | 3,963,910 | ​ | ​ | ​ |                                ​ | ​ |         — | ​ | ​ | ​ |    ​ | ​ | 3,963,910 | ​ | ​ |
| Stock options to purchase common stock        | ​ | ​ |                                  ​ | ​ | 1,216,642 | ​ | ​ | ​ |    ​ | ​ |   733,704 | ​ | ​ | ​ |                                ​ | ​ | 1,216,642 | ​ | ​ | ​ |    ​ | ​ |   733,704 | ​ | ​ |

13. Commitment and Contingencies Legal Matters The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the condensed consolidated balance sheets. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of June 30, 2025 and December 31, 2024, the Company was not a party to any material legal proceedings or claims other than those described below. Merger Proceedings Between December 20, 2024, and March 19, 2025, Cara received thirteen demands (and three draft complaints) from purported stockholders of Cara (collectively, the Demands) challenging the disclosures in the Proxy Statement/Prospectus related to the Merger and asserting claims for violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934. In addition, on March 5 and